Welcome to the CRYSVITA® website for Australian HCPs

What is XLH?

XLH is a rare, genetic, progressive and life-long phosphate wasting disorder, caused by mutations in the PHEX gene that leads to excess FGF232–7

How does CRYSVITA® work?

CRYSVITA® is a recombinant human monoclonal IgG1 antibody that binds to and inhibits the biological activity of fibroblast growth factor 23 (FGF23), present in excess in X-linked hypophosphataemia. Neutralisation of FGF23 by CRYSVITA®  increases renal tubular reabsorption of phosphate and the serum concentration of 1, 25 dihydroxy-Vitamin D. 1


The efficacy and safety of CRYSVITA® in children (aged ≥1 year) and adults with XLH has been studied in a global clinical development programme, comprising phase II and phase III clinical trials 8-13

Starting CRYSVITA®

CRYSVITA® is indicated for the treatment of X-linked hypophosphataemia (XLH) in adults, adolescents and children 1 year of age or older.1

Resources to support the management of XLH

Resources include a Dosing and Administration Guide, Injection Guide, Prescribing Guide, Patient Starter Guide and more.

1. Australian Product Information for Crysvita® (burosumab) approved 10 September 2021. https://www.kyowakirin.com/australia/our_medicines/doc/crysvita_product_information_leaflet.pdf. Last updated: Sept 2021 Last accessed: March 2023. 2. Beck-Nielsen SS, et al. Orphanet J Rare Dis. 2019;14:58. 3. Carpenter TO, et al. J Bone Miner Res. 2011;26:1381–88. 4. Endo I, et al. Endocr J. 2015;62:811–16. 5. Haffner D, et al. Nat Rev Nephrol. 2019;15:435–55. 6. Martin A & Quarles LD. Adv Exp Med Biol. 2012;728:65–83. 7. Rafaelsen S, et al. Eur J Endocrinol. 2016;174:125–36 8. Carpenter TO, et al. N Engl J Med. 2018;378:1987-98. 9. Whyte MP, et al. Lancet Diabetes Endocrinol 2019;7:189-99. 10. Imel EA, et al. Lancet. 2019;393:2416–27. 11. Insogna KL, et al. J Bone Miner Res. 2018;33:1383–93. 12. Portale AA, et al. Calcif Tissue Int. 2019;105:271–84. 13. Insogna KL, et al. J Bone Miner Res. 2019;34:2183–91.

See full list of references used on this page